Japanese patients with cold agglutinin disease (CAD) are almost three times more likely to develop blood clots compared with people…
Patricia Inácio, PhD
Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Patricia Inácio, PhD
The risk of blood clots nearly doubles in people with cold agglutinin disease (CAD) compared with that seen in…
The autoantibodies found in people with cold agglutinin disease (CAD) carry high levels of sugar molecules, which may…
The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However,…
The rare case of a man infected with the hepatitis E virus who developed autoimmune hemolytic anemia was described in…
The wrong blood type may be given to people with undiagnosed autoimmune hemolytic anemia (AIHA), which can lead to…
Treatment with blood transfusions is safe and efficient for treating hospitalized autoimmune hemolytic anemia (AIHA) patients, a large…
Nearly $200,000 Awarded to Cold Agglutinin Disease Foundation, Other Rare Disease Organizations
The Cold Agglutinin Disease Foundation is among 20 rare disease organizations receiving funding under Global Genes‘ 2020 RARE…
Cold agglutinin disease (CAD) patients have an increased risk of developing blood clots compared to the general population, a…
Arzerra a Potential Alternative to Rituxan for Patients with AIHA and Lupus, Case Report Suggests
Arzerra (ofatumumab) may be a promising alternative for the treatment of autoimmune hemolytic anemia (AIHA) in patients who…